Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study

Journal:

Arthritis & Rheumatology

Published:

2026-03-25

DOI:

10.1002/art.70152

Affiliations:

12

Authors:

13

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	4.000000	0.31
NYU Langone Health, United States of America (USA)	1.000000	0.08
University of Glasgow, United Kingdom (UK)	1.000000	0.08
Hospital Italiano de Buenos Aires, Argentina	1.000000	0.08
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	1.000000	0.08
University of New South Wales (UNSW Sydney), Australia	1.000000	0.08
University of California, San Francisco (UCSF), United States of America (USA)	1.000000	0.08
University of Rochester Medical Center (URMC), UR, United States of America (USA)	1.000000	0.08
University of Toronto (U of T), Canada	0.500000	0.04
University Health Network (UHN), U of T, Canada	0.500000	0.04
Providence Swedish, United States of America (USA)	0.500000	0.04
University of Washington (UW), United States of America (USA)	0.500000	0.04

Interested in Clinical Sciences?